![Yves Lévy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profilo
Yves Lévy is the founder of Linkinvax SA, serving as Chief Scientific Officer since 2020.
Mr. Lévy is currently the Director at Global HIV Vaccine Enterprise.
Formerly, Mr. Lévy was the Chairman & Chief Executive Officer at Institut National de la Santé & de la Recherche Médicale.
Posizioni attive di Yves Lévy
| Società | Posizione | Inizio |
|---|---|---|
Global HIV Vaccine Enterprise
 Global HIV Vaccine Enterprise Miscellaneous Commercial ServicesCommercial Services Develops preventive HIV vaccines | Direttore/Membro del Consiglio | - |
Linkinvax SA
 Linkinvax SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company to develops disrupt vaccine using a unique dendritic cell-targeting vaccine platform | Fondatore | 01/01/2020 |
Precedenti posizioni note di Yves Lévy
| Società | Posizione | Fine |
|---|---|---|
Institut National de la Santé & de la Recherche Médicale
 Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Research institute | Amministratore Delegato | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
16
Relazioni di 1° grado
3
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Institut National de la Santé & de la Recherche Médicale
Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Research institute | Commercial Services |
Global HIV Vaccine Enterprise
Global HIV Vaccine Enterprise Miscellaneous Commercial ServicesCommercial Services Develops preventive HIV vaccines | Commercial Services |
Linkinvax SA
Linkinvax SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company to develops disrupt vaccine using a unique dendritic cell-targeting vaccine platform | Commercial Services |
